Effects of Acute, Rapid Lowering of LDL Cholesterol With Alirocumab in Patients With STEMI Undergoing Primary PCI

NCT03718286 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

97

Enrollment

OTHER

Sponsor class

Conditions

ST Elevation Myocardial Infarction
Acute Coronary Syndrome
Hypercholesterolemia
Hyperlipidemias
Dyslipidemias
Physiological Effects of Drugs

Interventions

DRUG: Alirocumab
OTHER: Sham Control

Sponsor

Population Health Research Institute